Last reviewed · How we verify
SHR4640
SHR4640 is a small-molecule inhibitor that targets and blocks specific kinase pathways involved in cancer cell proliferation and survival.
At a glance
| Generic name | SHR4640 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SHR4640 is an investigational kinase inhibitor developed by Jiangsu HengRui Medicine. While the precise molecular target has not been widely disclosed in public literature, it is being evaluated in phase 3 clinical trials for oncology indications. The drug is designed to inhibit aberrant signaling pathways that drive tumor growth.
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (PHASE2)
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout (PHASE3)
- Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects (PHASE1)
- PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval (PHASE1)
- Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects (PHASE1)
- Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (PHASE2)
- Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (PHASE1)
- Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |